IDEX(IEX) - 2025 Q4 - Annual Results

Sales and Orders - Record sales of $899 million increased 4% on a reported basis and 1% organically for Q4 2025[4] - Record orders of $979 million increased 20% on a reported basis and 16% organically, primarily driven by strength in the HST segment[4] - Total net sales for the quarter ended December 31, 2025, reached $899.1 million, a 4% increase from $862.9 million in the same quarter of 2024[34] - For the year ended December 31, 2025, total net sales were $3,457.5 million, up 6% from $3,268.8 million in 2024[34] - Organic sales growth for the quarter was 1%, with a 5% increase in Health & Science Technologies and a 1% increase in Fluid & Metering Technologies, while Fire & Safety/Diversified Products saw a 5% decline[39] Financial Performance - Net income for the year ended December 31, 2025, was $482.5 million, compared to $504.6 million in 2024, reflecting a decrease of 4.2%[28] - Basic earnings per share attributable to IDEX for 2025 was $6.41, down from $6.66 in 2024[28] - Reported net income attributable to IDEX for Q4 2025 was $128.3 million, slightly up from $123.2 million in Q4 2024, a 0.8% increase[42] - Adjusted net income attributable to IDEX for the quarter was $157.2 million, reflecting an increase from $155.1 million in the prior year[40] - Adjusted net income attributable to IDEX for the year 2025 was $599.5 million, compared to $598.5 million in 2024, indicating a marginal growth of 0.2%[42] Cash Flow and Liquidity - Operating cash flow of $680 million increased 2% and was 141% of net income, up from 132%[4] - Free cash flow of $617 million increased 2% and yielded a conversion of 103%, up from 101%[4] - Cash flows from operating activities for the year ended December 31, 2025, were $680.4 million, compared to $668.1 million in 2024[32] - Cash flows from operating activities for Q4 2025 were $209.5 million, up from $172.6 million in Q4 2024, representing a 21.5% increase[42] - Free cash flow for the year ended December 31, 2025, was $616.8 million, compared to $603.0 million in 2024, reflecting a 2.9% growth[42] Segment Performance - Health & Science Technologies segment net sales increased 9% in Q4 2025, with organic sales up 5%[11] - Fluid & Metering Technologies segment net sales increased 2% in Q4 2025, with organic sales up 1%[15] Cost and Expenses - Corporate costs included in consolidated Adjusted EBITDA were $18.7 million during Q4 2025, relatively flat compared to $20.1 million in the prior year[17] - Adjusted EBITDA margin for Q4 2025 improved due to net productivity enhancements, including platform optimization savings and cost containment[21] - The company incurred restructuring expenses and asset impairments totaling $2.4 million for the quarter[40] - Restructuring expenses and asset impairments for the year ended December 31, 2025, totaled $20.7 million[43] Shareholder Returns - The company utilized $73 million for share repurchases in Q4 2025 and $248 million for the full year[4] - The company repurchased 0.4 million shares at a cost of $75.0 million during the quarter[21] Balance Sheet - Total assets increased to $6,927.0 million as of December 31, 2025, compared to $6,745.3 million in 2024[30] - Total liabilities decreased to $2,900.8 million in 2025 from $2,951.2 million in 2024[30] - IDEX's goodwill increased to $3,414.5 million in 2025 from $3,251.7 million in 2024, indicating ongoing investment in acquisitions[30]